文献速递神经肿瘤

分子生物标志物定义的脑肿瘤:美国的流行病学、有效性与完整性

Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
PubMed 文献 · Neuro Oncol · 2022-01-01

研究评估2018年美国脑肿瘤登记中分子标志物变量的完整性与有效性,并描述分子定义脑肿瘤类型的流行病学。脑分子标志物(BMM)编码完整性为75%-92%,编码有效性良好;报告了IDH野生型胶质母细胞瘤、IDH突变型星形细胞瘤等发病率。

要点

  • BMM在适用肿瘤类型中的完整性为75%-92%,编码有效性良好。
  • IDH野生型胶质母细胞瘤发病率为1.74(95%CI:1.69-1.78)。
  • IDH突变型星形细胞瘤WHO 2级发病率为0.14(95%CI:0.12-0.15),3级为0.15(95%CI:0.14-0.16),4级为0.07(95%CI:0.06-0.08)。

核心结论

  • 研究结果表明,开发专门的整合诊断变量是成功的,该变量提供了与准确诊断相关的脑肿瘤关键分子信息。

研究设计与样本

  • 研究在美国中央脑肿瘤登记处(Central Brain Tumor Registry of the United States)和NCI的监测、流行病学和最终结果(SEER)发病率数据库中识别2018年组织病理学确诊的脑肿瘤患者。
  • 评估了脑分子标志物(BMM)特定部位数据项的编码完整性和有效性,并额外评估了1p/19q状态、MGMT启动子甲基化、WHO分级数据项和新的ICD-O-3编码。

主要发现

  • BMM在适用肿瘤类型中的完整性为75%-92%,并显示出良好的编码有效性。
  • IDH野生型胶质母细胞瘤发病率为1.74(95%CI:1.69-1.78),而IDH突变型星形细胞瘤WHO 2级为0.14(95%CI:0.12-0.15)、3级为0.15(95%CI:0.14-0.16)、4级为0.07(95%CI:0.06-0.08)。
  • 无论WHO分级如何,IDH突变患病率在青少年和年轻成人患者中最高,且IDH突变型星形细胞瘤更常见MGMT启动子甲基化。
  • 在儿童型肿瘤中,H3K27M突变型弥漫性中线胶质瘤发病率为0.06(95%CI:0.05-0.07),SHH激活/TP53野生型髓母细胞瘤为0.03(95%CI:0.02-0.03),C19MC改变的伴多层菊形团胚胎性肿瘤和RELA融合室管膜瘤均<0.01。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selected molecular biomarkers were incorporated into the US cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables and described the epidemiology of molecularly defined brain tumor types. METHODS: Brain tumor patients with histopathologically confirmed diagnosis in 2018 were identified within the Central Brain Tumor Registry of the United States and NCI's Surveillance, Epidemiology, and End Results Incidence databases. The brain molecular markers (BMM) site-specific data item was assessed for coding completeness and validity. 1p/19q status, MGMT promoter methylation, WHO grade data items, and new ICD-O-3 codes were additionally evaluated. These data were used to profile the characteristics and age-adjusted incidence rates per 100 000 population of molecularly defined brain tumors with 95% confidence intervals (95% CI). RESULTS: BMM completeness across the applicable tumor types was 75%-92% and demonstrated favorable coding validity. IDH-wildtype glioblastomas' incidence rate was 1.74 (95% CI: 1.69-1.78), as compared to 0.14 for WHO grade 2 (95% CI: 0.12-0.15), 0.15 for grade 3 (95% CI: 0.14-0.16), and 0.07 for grade 4 (95% CI: 0.06-0.08) IDH-mutant astrocytomas. Irrespective of WHO grade, IDH mutation prevalence was highest in adolescent and young adult patients, and IDH-mutant astrocytomas were more frequently MGMT promoter methylated. Among pediatric-type tumors, the incidence rate was 0.06 for H3K27M-mutant diffuse midline gliomas (95% CI: 0.05-0.07), 0.03 for SHH-activated/TP53-wildtype medulloblastomas (95% CI: 0.02-0.03), and <0.01 for both C19MC-altered embryonal tumor with multilayered rosettes and RELA-fusion ependymomas. CONCLUSIONS: Our findings illustrate the success of developing a dedicated, integrated diagnosis variable, which provides critical molecular information about brain tumors related to accurate diagnosis.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Iorgulescu JB, Sun C, Neff C, et al. Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro Oncol. 2022. PMID: 35460555. doi:10.1093/neuonc/noac113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。